10-K/A: IMAC Holdings Restates 2023 Annual Report Amidst Strategic Shift and Merger Plans

IMAC Holdings files an amended 10-K, restating its financials and detailing its strategic shift away from clinic operations towards a merger with Theralink Technologies.

Summary

• IMAC Holdings has filed an amended annual report on Form 10-K/A for the fiscal year ended December 31, 2023, restating the original filing in its entirety.
• The company has closed or sold all of its outpatient medical clinics and BackSpace locations as of December 31, 2023, marking a significant shift in its business strategy.
• IMAC Holdings reported a net loss of approximately $9.4 million for 2023, compared to a net loss of $18.3 million in 2022.
• The company's revenue from discontinued operations was approximately $5.2 million in 2023, a significant decrease from $16.2 million in 2022.
• The company is pursuing a merger with Theralink Technologies, with the merger agreement unanimously approved by both boards of directors.
• IMAC Holdings has entered into a credit agreement with Theralink, providing up to $1 million in loans, with an initial borrowing of $350,000.
• The company completed a series of transactions on April 11, 2024, including the exchange of Series B preferred stock for new preferred stock and the sale of new preferred stock and warrants, resulting in gross proceeds of $900,000.
• The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern due to recurring losses and a net capital deficiency.

Sentiment

Score: 3

Explanation: The document indicates significant financial challenges, including substantial losses, declining revenue, and a going concern qualification. While there are some positive developments, such as the merger plans and recent capital raise, the overall sentiment is negative due to the company's precarious financial position and operational restructuring.

Positives

• The company's net loss decreased significantly year-over-year, from $18.3 million to $9.4 million.
• The company has secured $900,000 in funding through the sale of new preferred stock and warrants.
• The company is actively pursuing a merger with Theralink Technologies, which could provide a new strategic direction.

Negatives

• The company has ceased operations at all of its outpatient medical clinics and BackSpace locations.
• The company's revenue from discontinued operations decreased significantly year-over-year.
• The company's auditor has raised concerns about its ability to continue as a going concern.
• The company has a working capital deficit of $(0.8) million as of December 31, 2023.

Risks

• The company's ability to continue as a going concern is in doubt due to recurring losses and a net capital deficiency.
• The company may not be able to obtain additional financing on acceptable terms, or at all.
• The company's merger with Theralink Technologies is subject to various closing conditions and may not be consummated.
• The company's stock price is volatile and an investment could decline in value.
• The company may not be able to maintain its listing on Nasdaq.
• The company has identified material weaknesses in its internal controls over financial reporting.

Future Outlook

The company is focused on completing the merger with Theralink Technologies and evaluating strategic alternatives to support operations in 2024 and beyond. The company anticipates needing to raise additional capital to fund future operations.

Management Comments

• Management has been actively exploring various strategic alternatives since July 2022.
• Management has determined that the company's financial condition raises substantial doubt as to its ability to continue as a going concern.

Industry Context

The healthcare industry is undergoing significant changes, with increasing pressure on pricing and a shift towards value-based care. IMAC Holdings' strategic shift reflects these trends, as the company moves away from traditional clinic operations and explores new opportunities through a merger.

Comparison to Industry Standards

• The closure of all IMAC clinics and BackSpace locations is a significant departure from the typical operations of healthcare service providers, indicating a major strategic shift.
• The company's financial performance, with substantial losses and declining revenue, is significantly below industry benchmarks for established healthcare companies.
• The pursuit of a merger with Theralink Technologies is a strategic move to potentially diversify and leverage new technologies, which is a common strategy in the healthcare sector to adapt to changing market conditions.
• The company's reliance on external financing and strategic alliances is a common practice for early-stage companies in the healthcare industry, but the going concern qualification raises concerns about its financial stability compared to industry peers.
• The company's focus on regenerative medicine and minimally invasive procedures aligns with the trend towards non-opioid pain management solutions, but the closure of clinics indicates a failure to execute this strategy effectively.

Management Changes

Legal Proceedings

• The company is involved in ongoing audits by CMS contractors, with potential overpayment claims.
• The company is appealing a decision from a Qualified Independent Contractor regarding medical necessity claims.

Related Party Transactions

• The company paid $0 and $27,000 to The MOLO Agency, owned by board member Maurice Evans, for marketing services in 2023 and 2022, respectively.

Stakeholder Impact

• Shareholders face significant risks due to the company's financial instability and potential delisting.
• Employees have been impacted by the closure of all clinics and the resulting job losses.
• Patients have been affected by the discontinuation of services at all IMAC locations.
• Creditors face uncertainty regarding the company's ability to repay its debts.

Next Steps

• The company will seek stockholder approval for the issuance of securities related to the Series C Preferred Stock and Warrants by July 31, 2024.
• The company will continue to evaluate all options with respect to the structuring of the business combination with Theralink Technologies.
• The company will continue to explore various strategic alternatives to support operations in 2024 and beyond.

Key Dates

Keywords

IMAC Holdings, Theralink Technologies, merger, discontinued operations, financial results, going concern, preferred stock, warrants, capital raise, restatement, reverse stock split